Cold agglutinin disease (CAD) is a rare subtype of autoimmune haemolytic anaemia (AIHA) where autoantibodies, predominantly of the IgM class, bind to red blood cells at reduced temperatures. This ...
Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Paris, November 17, 2022. The European Commission (EC) has ...
This was a case report and literature review, aimed to strengthen the understanding and therapy of mycoplasma pneumoniae (MP) pneumonia combined with cold agglutinin disease and pulmonary embolism in ...
The U.S. FDA has approved Sanofi SA’s treatment for cold agglutinin disease (CAD), sutimlimab, after the drug was initially rejected by the regulator for technical reasons in 2020. Paris-based ...
Oct 4 (Reuters) - Italian pharma group Recordati (RECI.MI), opens new tab said on Friday it would buy from Sanofi (SASY.PA), opens new tab the global rights to a drug used to treat cold agglutinin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback